Acelrx Pharmaceuticals reported $-8211000 in EBITDA for its second fiscal quarter of 2022.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Ebitda Change
Acelrx Pharmaceuticals ACRX:US $ -8.21M 0.36M
Baxter International BAX:US $ 787M 124M
Becton, Dickinson and BDX:US $ 1182M 180M
Cara Therapeutics CARA:US $ -4409000 23.44M
Intra Cellular Therapies ITCI:US $ -87.75M 15.26M
Johnson & Johnson JNJ:US $ 8036M 1273M
Pain Therapeutics PTIE:US $ -19.62M 2.11M
Pfizer PFE:US $ 12921M 1739M
Smiths SMIN:LN 228M 56M
Teva Pharmaceutical TEVA:IT 1.09B 20M
Xeris Pharmaceuticals Inc XERS:US $ -15854000 188K